A Review on new drugs for treatment of Polycystic Ovarian Syndrome


Polycystic ovary syndrome( PCOS) is a most common prevalent endocrine disorder in females at reproductive period. Metabolic pathophysiology and sequelae associated with this syndrome range from insulin resistance to it is complication such as obesity, infertility , diabetes , and cardiovascular diseases . Insulin resistance plays a potential role in this pathophysiology , this makes counteract this resistance as the first –line treatment in PCOS .So various clinical trials have tried to control clinical and biochemical aspects of this disorder. Although traditional insulin sensitizing drugs such as metformin and pioglitazone and Antiandrogens have been used for treatment metabolic and clinical aspects of PCOS , however their efficacy is not significant in terms of obesity and cardiovascular risk reduction compared with more recent insulin sensitizers such as incretin mimetics ( glucagon like peptide -1 agonists and Dipeptidyl peptidase- 4 inhibitors) , sodium glucose cotransporter -2 inhibitors and other miscellaneous treatment including statins , melatonin and vitamin D3.This current pharmacological advances and potential therapeutic strategies giving patients and clinicians more choices.